CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER Russian patent published in 2019 - IPC A61K39/395 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns a pharmaceutical composition for treating solid cancer or inhibiting cancer cell containing CD43 antibody (differentiation cluster 43) or its antigen-binding fragment, wherein said CD43 antibody or antigen-binding fragment thereof contains CDR1H with SEQ ID NO: 110, CDR2H with SEQ ID NO: 113, CDR3H with SEQ ID NO: 118, CDR1L with SEQ ID NO: 119, CDR2L with SEQ ID NO: 120 and CDR3L with SEQ ID NO: 125, wherein said antibody or its antigen-binding fragment binds to an epitope consisting of 6-9 consecutive amino acids in the amino acid sequence SEQ ID NO: 134, and where said 6–9 consecutive amino acids contain the amino acid sequence SEQ ID NO: 131. Group of inventions also relates to a method for screening an agent for treating solid cancer or inhibiting cancerous stem cell; nucleic acid molecules encoding said CD43 antibody or antigen-binding fragment thereof; recombinant vector containing said nucleic acid molecule.

EFFECT: group of inventions provides treating solid cancer or inhibiting cancer stem cell.

24 cl, 20 ex, 46 dwg, 4 tbl